The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Pharmacokinetic and safety profile of trans‐resveratrol in a rising multiple‐dose study in healthy volunteers
Abstract
This was a double‐blind, randomised, placebo‐controlled study to investigate the pharmacokinetics and safety of trans‐resveratrol. In four groups of ten healthy adult subjects (five males and five females), two subjects were randomized to receive placebo and eight subjects to receive trans‐resveratrol 25, 50, 100 or 150 mg, six times/day, for thirteen doses. Peak plasma concentrations of trans‐resveratrol were reached at 0.8–1.5 h postdose. Following the 13th dose of trans‐resveratrol 25, 50, 100 and 150 mg, mean peak plasma concentration (Cmax) was 3.89, 7.39, 23.1 and 63.8 ng/mL and mean area under the plasma concentration–time curve (AUC 0‐τ) was 3.1, 11.2, 33.0 and 78.9 ng·h/mL. Interindividual variability was high, with coefficients of variation >40%.Trans‐resveratrol half‐life was 1–3 h following single‐doses and 2–5 h following repeated dosing. Trough (Cmin) concentrations were ⪇1 ng/mL following 25 and 50 mg, 3 ng/mL following 100 mg and < 10 ng/mL following 150 mg.Trans‐resveratrol pharmacokinetics showed circadian variation. Adverse events were mild in severity and similar between all groups. In conclusion, repeated administration was well‐tolerated but produced relatively low plasma concentrations of trans‐resveratrol, despite the high doses and short dosing interval used. Bioavailability was higher after morning administration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
HIGH ABSORPTION BUT VERY LOW BIOAVAILABILITY OF ORAL RESVERATROL IN HUMANS
Walle, T., Hsieh, F., DeLegge, M. H., Oatis, J. E., & Walle, U. K. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.000885 · Cited by 1,880
Biological effects of resveratrol
Frémont, L. (2000) · Life Sciences · doi:10.1016/s0024-3205(99)00410-5 · Cited by 1,663
Boocock, D. J., Faust, G. E. S., Patel, K. R., Schinas, A. M., Brown, V. A., Ducharme, M. P., Booth, T. D., Crowell, J. A., Perloff, M., Gescher, A. J., et al. (2007) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-07-0022 · Cited by 824
Resveratrol as an anti-inflammatory and anti-aging agent: Mechanisms and clinical implications
Alarcón de la Lastra, C., & Villegas, I. (2005) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.200500022 · Cited by 703
Metabolism and bioavailability oftrans-resveratrol
Wenzel, E., & Somoza, V. (2005) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.200500010 · Cited by 676
Biological Effects of Resveratrol
Bhat, K. P. L., Kosmeder, J. W., & Pezzuto, J. M. (2001) · Antioxidants & Redox Signaling · doi:10.1089/152308601317203567 · Cited by 507
Marier, J.-F., Vachon, P., Gritsas, A., Zhang, J., Moreau, J.-P., & Ducharme, M. P. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.033340 · Cited by 480
Resveratrol as a Chemopreventive Agent: A Promising Molecule for Fighting Cancer
Delmas, D., Lancon, A., Colin, D., Jannin, B., & Latruffe, N. (2006) · Current Drug Targets · doi:10.2174/138945006776359331 · Cited by 395
Kopp, P. (1998) · European Journal of Endocrinology · doi:10.1530/eje.0.1380619 · Cited by 392
Resveratrol—A boon for treating Alzheimer's disease?
Anekonda, T. S. (2006) · Brain Research Reviews · doi:10.1016/j.brainresrev.2006.04.004 · Cited by 339
Cited by
Del Rio, D., Rodriguez-Mateos, A., Spencer, J. P. E., Tognolini, M., Borges, G., & Crozier, A. (2013) · Antioxidants & Redox Signaling · doi:10.1089/ars.2012.4581 · Cited by 2,601
“Gastric absorption explains the peak of free resveratrol in the plasma 30 min after ingestion (8, 39, 475, 479).”
Antioxidant Phytochemicals for the Prevention and Treatment of Chronic Diseases
Zhang, Y.-J., Gan, R.-Y., Li, S., Zhou, Y., Li, A.-N., Xu, D.-P., & Li, H.-B. (2015) · Molecules · doi:10.3390/molecules201219753 · Cited by 1,369
Bioavailability of resveratrol
Walle, T. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05842.x · Cited by 1,051
Polyphenols and Human Health: Prevention of Disease and Mechanisms of Action
Vauzour, D., Rodriguez-Mateos, A., Corona, G., Oruna-Concha, M. J., & Spencer, J. P. E. (2010) · Nutrients · doi:10.3390/nu2111106 · Cited by 855
Gambini, J., Inglés, M., Olaso, G., Lopez-Grueso, R., Bonet-Costa, V., Gimeno-Mallench, L., Mas-Bargues, C., Abdelaziz, K. M., Gomez-Cabrera, M. C., Vina, J., et al. (2015) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2015/837042 · Cited by 737
Brown, V. A., Patel, K. R., Viskaduraki, M., Crowell, J. A., Perloff, M., Booth, T. D., Vasilinin, G., Sen, A., Schinas, A. M., Piccirilli, G., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-2364 · Cited by 688
Clinical Pharmacology of Resveratrol and Its Metabolites in Colorectal Cancer Patients
Patel, K. R., Brown, V. A., Jones, D. J. L., Britton, R. G., Hemingway, D., Miller, A. S., West, K. P., Booth, T. D., Perloff, M., Crowell, J. A., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-2027 · Cited by 624
Administration of resveratrol: What formulation solutions to bioavailability limitations?
Amri, A., Chaumeil, J. C., Sfar, S., & Charrueau, C. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.09.083 · Cited by 620
Resveratrol and health—A comprehensive review of human clinical trials
Smoliga, J. M., Baur, J. A., & Hausenblas, H. A. (2011) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201100143 · Cited by 594
Resveratrol bioavailability and toxicity in humans
Cottart, C., Nivet‐Antoine, V., Laguillier‐Morizot, C., & Beaudeux, J. (2010) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.200900437 · Cited by 592
Resveratrol (RV): A pharmacological review and call for further research
Zhang, L.-X., Li, C.-X., Kakar, M. U., Khan, M. S., Wu, P.-F., Amir, R. M., Dai, D.-F., Naveed, M., Li, Q.-Y., Saeed, M., et al. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112164 · Cited by 546
Health benefits of resveratrol: Evidence from clinical studies
Singh, A. P., Singh, R., Verma, S. S., Rai, V., Kaschula, C. H., Maiti, P., & Gupta, S. C. (2019) · Medicinal Research Reviews · doi:10.1002/med.21565 · Cited by 523
Clinical trials of resveratrol
Patel, K. R., Scott, E., Brown, V. A., Gescher, A. J., Steward, W. P., & Brown, K. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05853.x · Cited by 522
The molecular targets of resveratrol
Kulkarni, S. S., & Cantó, C. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.10.005 · Cited by 477
“plasma are either not detectable or clearly below the micromolar range [19,20], as used in vitro.”
MethodHigh-Dose Resveratrol Supplementation in Obese Men
Poulsen, M. M., Vestergaard, P. F., Clasen, B. F., Radko, Y., Christensen, L. P., Stødkilde-Jørgensen, H., Møller, N., Jessen, N., Pedersen, S. B., & Jørgensen, J. O. L. (2013) · Diabetes · doi:10.2337/db12-0975 · Cited by 455
Resveratrol: French Paradox Revisited
Catalgol, B., Batirel, S., Taga, Y., & Ozer, N. K. (2012) · Frontiers in Pharmacology · doi:10.3389/fphar.2012.00141 · Cited by 449
Resveratrol and Clinical Trials: The Crossroad from In Vitro Studies to Human Evidence
Tomé-Carneiro, J., Larrosa, M., González-Sarrías, A., Tomás-Barberán, F., García-Conesa, M., & Espín, J. (2013) · Current Pharmaceutical Design · doi:10.2174/13816128113199990407 · Cited by 449
Howells, L. M., Berry, D. P., Elliott, P. J., Jacobson, E. W., Hoffmann, E., Hegarty, B., Brown, K., Steward, W. P., & Gescher, A. J. (2011) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-11-0148 · Cited by 444
What Is New for an Old Molecule? Systematic Review and Recommendations on the Use of Resveratrol
Vang, O., Ahmad, N., Baile, C. A., Baur, J. A., Brown, K., Csiszar, A., Das, D. K., Delmas, D., Gottfried, C., Lin, H.-Y., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019881 · Cited by 437
Kennedy, D. O., Wightman, E. L., Reay, J. L., Lietz, G., Okello, E. J., Wilde, A., & Haskell, C. F. (2010) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.2009.28641 · Cited by 415
Neuroprotective Mechanisms of Resveratrol in Alzheimer’s Disease: Role of SIRT1
Gomes, B. A. Q., Silva, J. P. B., Romeiro, C. F. R., dos Santos, S. M., Rodrigues, C. A., Gonçalves, P. R., Sakai, J. T., Mendes, P. F. S., Varela, E. L. P., & Monteiro, M. C. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/8152373 · Cited by 403
Resveratrol: Its Biologic Targets and Functional Activity
Pervaiz, S., & Holme, A. L. (2009) · Antioxidants & Redox Signaling · doi:10.1089/ars.2008.2412 · Cited by 405
Polyphenols and Human Health: A Prospectus
Visioli, F., Lastra, C. A. D. L., Andres-Lacueva, C., Aviram, M., Calhau, C., Cassano, A., D’Archivio, M., Faria, A., Favé, G., Fogliano, V., et al. (2011) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408391003698677 · Cited by 339
Enhancing the bioavailability of resveratrol by combining it with piperine
Johnson, J. J., Nihal, M., Siddiqui, I. A., Scarlett, C. O., Bailey, H. H., Mukhtar, H., & Ahmad, N. (2011) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201100117 · Cited by 339
Zordoky, B. N. M., Robertson, I. M., & Dyck, J. R. B. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.10.016 · Cited by 335
Resveratrol nanoformulations: Challenges and opportunities
Summerlin, N., Soo, E., Thakur, S., Qu, Z., Jambhrunkar, S., & Popat, A. (2015) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2015.01.003 · Cited by 316
Progress to Improve Oral Bioavailability and Beneficial Effects of Resveratrol
Chimento, A., De Amicis, F., Sirianni, R., Sinicropi, M. S., Puoci, F., Casaburi, I., Saturnino, C., & Pezzi, V. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061381 · Cited by 310
Metabolism and pharmacokinetics of resveratrol and pterostilbene
Wang, P., & Sang, S. (2018) · BioFactors · doi:10.1002/biof.1410 · Cited by 289
Reinisalo, M., Kårlund, A., Koskela, A., Kaarniranta, K., & Karjalainen, R. O. (2015) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2015/340520 · Cited by 284
Wong, R. H. X., Howe, P. R. C., Buckley, J. D., Coates, A. M., Kunz, I., & Berry, N. M. (2011) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2010.03.003 · Cited by 277
Lifespan and healthspan extension by resveratrol
Bhullar, K. S., & Hubbard, B. P. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.01.012 · Cited by 274
Anti-inflammatory activity of natural stilbenoids: A review
Dvorakova, M., & Landa, P. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.08.002 · Cited by 268
Resveratrol and cancer: Challenges for clinical translation
Singh, C. K., Ndiaye, M. A., & Ahmad, N. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.11.004 · Cited by 265
la Porte, C., Voduc, N., Zhang, G., Seguin, I., Tardiff, D., Singhal, N., & Cameron, D. W. (2010) · Clinical Pharmacokinetics · doi:10.2165/11531820-000000000-00000 · Cited by 261
Clinical trials of antioxidants as cancer prevention agents: Past, present, and future
Goodman, M., Bostick, R. M., Kucuk, O., & Jones, D. P. (2011) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.05.018 · Cited by 255
Resveratrol: review on therapeutic potential and recent advances in drug delivery
Pangeni, R., Sahni, J. K., Ali, J., Sharma, S., & Baboota, S. (2014) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2014.919253 · Cited by 255
Griñán-Ferré, C., Bellver-Sanchis, A., Izquierdo, V., Corpas, R., Roig-Soriano, J., Chillón, M., Andres-Lacueva, C., Somogyvári, M., Sőti, C., Sanfeliu, C., et al. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101271 · Cited by 208
Antioxidant Effects of Resveratrol in Cardiovascular, Cerebral and Metabolic Diseases
Carrizzo, A., Forte, M., Damato, A., Trimarco, V., Salzano, F., Bartolo, M., Maciag, A., Puca, A. A., & Vecchione, C. (2013) · Food and Chemical Toxicology · doi:10.1016/j.fct.2013.07.021 · Cited by 203
Translating dosages from animal models to human clinical trials—revisiting body surface area scaling
Blanchard, O. L., & Smoliga, J. M. (2015) · The FASEB Journal · doi:10.1096/fj.14-269043 · Cited by 183
“[2009 (56)], which resulted in a Cmax of 21.”
BackgroundChronic resveratrol consumption improves brachial flow-mediated dilatation in healthy obese adults
Wong, R. H. X., Berry, N. M., Coates, A. M., Buckley, J. D., Bryan, J., Kunz, I., & Howe, P. R. C. (2013) · Journal of Hypertension · doi:10.1097/hjh.0b013e328362b9d6 · Cited by 162
“Resveratrol is known to metabolize rapidly in humans, even after oral administration of doses ranging from 25 to 150 mg repeated six times per day [26].”
BackgroundMetabolic effects of resveratrol: Addressing the controversies
Bitterman, J. L., & Chung, J. H. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1808-8 · Cited by 109
Role of dietary bioactive natural products in estrogen receptor-positive breast cancer
Bak, M. J., Das Gupta, S., Wahler, J., & Suh, N. (2016) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2016.03.001 · Cited by 80
Resveratrol improves sperm DNA quality and reproductive capacity in type 1 diabetes
Simas, J. N., Mendes, T. B., Fischer, L. W., Vendramini, V., & Miraglia, S. M. (2021) · Andrology · doi:10.1111/andr.12891 · Cited by 39
Role of Drug Delivery System in Improving the Bioavailability of Resveratrol
Saleem, Z., Rehman, K., & Hamid Akash, M. S. (2022) · Current Pharmaceutical Design · doi:10.2174/1381612828666220705113514 · Cited by 34
Dose response biology of resveratrol in obesity
Scapagnini, G., Davinelli, S., Kaneko, T., Koverech, G., Koverech, A., Calabrese, E. J., & Calabrese, V. (2014) · Journal of Cell Communication and Signaling · doi:10.1007/s12079-014-0257-3 · Cited by 31
“The detailed pharmacokinetics of resveratrol in humans and rodents have been studied (Almeida et al. 2009) and recent studies have shown that resveratrol binds several receptors and signalling molecules, and inhibits the functions of key receptors, kinases, proteinases and other enzymes involved in metabolic pathways…”
BackgroundPosey, K. L. (2024) · Biomolecules · doi:10.3390/biom14020154 · Cited by 20
Metadata
- Authors
- Almeida, L., Vaz‐da‐Silva, M., Falcão, A., Soares, E., Costa, R., Loureiro, A. I., Fernandes‐Lopes, C., Rocha, J., Nunes, T., Wright, L., & Soares‐da‐Silva, P.
- Venue
- Molecular Nutrition & Food Research
- Publisher
- Wiley
- Published
- 2009-05
- Volume
- 53
- Issue
- S1
- Pages
- S7-15
- ISSN
- 1613-4125 (ISSN-L)
- 1613-4133
- OpenAlex
- W2051990086
- Cited by
- 426
- References
- 21
- FWCI
- 16.97
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.